July 2018 - Botanix Pharmaceuticals (ASX:BOT) Founder and Executive Director Matthew Callahan outlines how the medical dermatology company is improving the lives of patients suffering from serious skin diseases including acne, psoriasis and atopic dermatitis using a novel therapeutic and advanced transdermal drug delivery system.
Mr Callahan also highlights Botanix Pharmaceuticals’ key achievements and details the experience on the company’s board and team.
To learn more please visit: www.botanixpharma.com
Botanix Pharmaceuticals (ASX:BOT) Introduction
Теги
Botanix PharmaceuticalsBotanix PharmaBotanixASX:BOTMatthew CallahanMatt Callahanskinacnepsoriasisatopic dermatitisdermatologymedicinescienceresearchskin newsmedical newsscience newsASXstocksASX stockssmall capsASX newsstocks newsfinancefinance newsinvestinvestmentnewswealthmoneymoney newsinterviewvideoAustraliaAustralia newsinvesting news
